The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

The agency recommends manufacturers update their vaccines to target the JN.1 strain. At the same time, HHS head Robert F.

The FDA has placed a clinical hold on the study while Rocket works with trial monitors and experts to investigate the cause ...

The startup is the latest beneficiary of investors’ appetite for protein-degrading technology, which offers a way to reach ...